- Home
- PFD vs PLX Comparison
PFD vs PLX Comparison
Compare PFD & PLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFD | PLX |
|---|---|---|
| Founded | 1990 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 152.5M | 142.3M |
| IPO Year | N/A | 1998 |
Fundamental Metrics
Financial Performance| Metric | PFD | PLX |
|---|---|---|
| Price | $11.78 | $2.02 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | 33.2K | ★ 836.6K |
| Earning Date | 01-01-0001 | 11-13-2025 |
| Dividend Yield | ★ 6.30% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.07 |
| Revenue | N/A | ★ $61,840,000.00 |
| Revenue This Year | N/A | $14.29 |
| Revenue Next Year | N/A | $16.65 |
| P/E Ratio | ★ N/A | $29.53 |
| Revenue Growth | N/A | ★ 35.41 |
| 52 Week Low | $8.53 | $1.32 |
| 52 Week High | $11.18 | $3.10 |
Technical Indicators
Market Signals| Indicator | PFD | PLX |
|---|---|---|
| Relative Strength Index (RSI) | 43.05 | 59.47 |
| Support Level | $11.77 | $1.97 |
| Resistance Level | $12.07 | $2.11 |
| Average True Range (ATR) | 0.13 | 0.10 |
| MACD | -0.01 | 0.03 |
| Stochastic Oscillator | 17.71 | 73.49 |
Price Performance
Historical ComparisonAbout PFD Flaherty & Crumrine Preferred and Income Fund Incorporated
Flaherty & Crumrine Prefd Inc Fund Inc is a United States-based diversified, closed-end management investment company. Its investment objective is to provide its common shareholders with high current income consistent with the preservation of capital. The fund invests in a diversified portfolio of preferred securities, which includes traditional preferred stocks eligible for the inter-corporate dividends received a deduction and fully taxable preferred securities.
About PLX Protalix BioTherapeutics Inc. (DE)
Protalix BioTherapeutics Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system or ProCellEx. It has developed taliglucerase alfa for the treatment of Gaucher disease. The company's products also treat diseases like Fabry disease and cystic fibrosis. The company's primary sources of revenue include its sales of BioManguinhos alfataliglicerase in Brazil and of drug substances to Pfizer under its Amended Pfizer Agreement. The company's pipeline consists of ELFABRIO, Uricase, and Long Acting DNase I.